Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenapanor in Hyperphosphatemia (NORMALIZE)
NCT03988920Phase 4Completed
- Sponsor
- Ardelyx
- Start
- Jun 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenapanor in hyperphosphatemia (2 arms), sponsored by Ardelyx. Primary endpoint: Achieving Normal Serum Phosphorus Level at 18 months. Started Jun 2019; status: completed.
02
Drugs
tenapanor
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT03988920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988920.